/
Other
Fibrosis
159
Pipeline Programs↗
194
Active Trials↗
126
Companies Involved↗
Fibrosis is a highly competitive landscape with 159 programs across 126 companies. The most active players are Endeavor Biomedicines, Inc., Hepion Pharmaceuticals, Inc.. 25 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical71
Phase 113
Phase 250
Phase 325
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
124 of 133 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 133 classified programs, each share of the total. Modality classified for 94% of 159 pipeline programs.
Analysis
Trial Status
1,012
clinical trials
Completed591 · 58%
Recruiting113 · 11%
Terminated101 · 10%
Unknown status79 · 8%
Active, not recruiting39 · 4%
Not yet recruiting37 · 4%
Other52 · 5%
Clinical Trials
Trial Activity
1012 trials
Natural History of Noncirrhotic Portal Hypertension
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT02417740·400 enrolled
Page 1 of 68
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)